PeerJ· 2026Q1
The role of SARS1 in the progression of colorectal cancer: insights from clinical data and organoid models
- 0citations
- Q1SCImago
- 2026year
Short summary
High SARS1 expression in colorectal adenomas and cancers correlates with better patient survival (OS and PFS), and its knockdown in organoids promotes cancer-like gene expression and cell proliferation.
AI-generated from the title and abstract; the full text is not read.
Key points
- SARS1 expression is significantly higher in adenomas and cancers than in normal colorectal mucosa.
- SARS1 expression decreases from the adenoma stage to the cancer stage.
- High SARS1 expression is associated with improved overall survival (P=0.0209) and progression-free survival (P=0.0147) in CRC patients.
- Knockdown of SARS1 in adenoma organoids alters gene expression (decreased LGR5/OLFM4, increased c-Myc) and enhances cell proliferation and organoid viability.
AI-generated from the title and abstract; the full text is not read.
Abstract
Colorectal cancer (CRC) is a significant global health concern, with adenomas representing critical precancerous lesions. Early detection of adenomas is essential for reducing the incidence of CRC; however, effective biomarkers for the adenoma–carcinoma transition are currently lacking. Serine tRNA ligase (SARS1) has been identified in colorectal adenoma tissues, but its biological role remains unclear. Here, we analyzed SARS1 expression in colorectal adenoma and colorectal cancer using data from the GEO and TCGA databases, as well as immunohistochemical staining of 48 tissue pairs (normal colorectal mucosa, adenoma lesion, and cancer lesion). SARS1 expression was significantly higher in adenomas and cancers compared to normal colorectal mucosa, decreasing from the adenoma to cancer stages. High SARS1 expression was associated with improved overall survival (OS; Log-rank P = 0.0209) and progression-free survival (PFS; Log-rank P = 0.0147) in patients with CRC. As demonstrated by immunofluorescence and qRT-PCR, in colorectal adenoma organoids, SARS1 knockdown was associated with decreased expression of LGR5 and OLFM4, and increased expression of c-Myc. This gene expression profile mirrors that observed in colorectal cancer organoids, as reported in previous studies. Additionally, the downregulation of SARS1 also enhanced the proliferation of CRC cells and the viability of colorectal adenoma organoids ( p < 0.01 to p < 0.0001). Our findings suggest that SARS1 exerts context-dependent, stage-associated growth-suppressive effects during the adenoma-to-carcinoma transition, and its downregulation is associated with colorectal cancer progression. SARS1 represents a candidate marker reflecting adenoma-to-carcinoma progression; however, its clinical utility as a diagnostic or prognostic tool requires independent validation in larger, independent, adequately powered cohorts, and its precise functional mechanisms warrant further investigation.
The authors' abstract, as published at the source. PeerJ, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine